JPWO2020160458A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020160458A5 JPWO2020160458A5 JP2021544547A JP2021544547A JPWO2020160458A5 JP WO2020160458 A5 JPWO2020160458 A5 JP WO2020160458A5 JP 2021544547 A JP2021544547 A JP 2021544547A JP 2021544547 A JP2021544547 A JP 2021544547A JP WO2020160458 A5 JPWO2020160458 A5 JP WO2020160458A5
- Authority
- JP
- Japan
- Prior art keywords
- acid sequence
- amino acid
- grn
- optionally
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 265
- 102000019204 Progranulins Human genes 0.000 claims description 121
- 108010012809 Progranulins Proteins 0.000 claims description 121
- 238000000034 method Methods 0.000 claims description 100
- 108060003393 Granulin Proteins 0.000 claims description 95
- 102000017941 granulin Human genes 0.000 claims description 95
- YIEDSISPYKQADU-UHFFFAOYSA-N n-acetyl-n-[2-methyl-4-[(2-methylphenyl)diazenyl]phenyl]acetamide Chemical compound C1=C(C)C(N(C(C)=O)C(=O)C)=CC=C1N=NC1=CC=CC=C1C YIEDSISPYKQADU-UHFFFAOYSA-N 0.000 claims description 94
- 210000004027 cell Anatomy 0.000 claims description 77
- 239000008194 pharmaceutical composition Substances 0.000 claims description 56
- 108700019146 Transgenes Proteins 0.000 claims description 34
- 208000027626 Neurocognitive disease Diseases 0.000 claims description 28
- 239000000203 mixture Substances 0.000 claims description 19
- 201000011240 Frontotemporal dementia Diseases 0.000 claims description 13
- 230000035772 mutation Effects 0.000 claims description 13
- 101001076292 Homo sapiens Insulin-like growth factor II Proteins 0.000 claims description 12
- 108020001507 fusion proteins Proteins 0.000 claims description 12
- 102000037865 fusion proteins Human genes 0.000 claims description 12
- 102000057877 human IGF2 Human genes 0.000 claims description 12
- 208000002339 Frontotemporal Lobar Degeneration Diseases 0.000 claims description 11
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 claims description 10
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 claims description 10
- 102000048143 Insulin-Like Growth Factor II Human genes 0.000 claims description 9
- 108090001117 Insulin-Like Growth Factor II Proteins 0.000 claims description 9
- 230000001149 cognitive effect Effects 0.000 claims description 9
- 101710095339 Apolipoprotein E Proteins 0.000 claims description 8
- 102100029470 Apolipoprotein E Human genes 0.000 claims description 8
- 102000003746 Insulin Receptor Human genes 0.000 claims description 8
- 108010001127 Insulin Receptor Proteins 0.000 claims description 8
- 108010076504 Protein Sorting Signals Proteins 0.000 claims description 8
- 238000003776 cleavage reaction Methods 0.000 claims description 8
- 230000007017 scission Effects 0.000 claims description 8
- 210000000130 stem cell Anatomy 0.000 claims description 8
- 108090001126 Furin Proteins 0.000 claims description 7
- 210000000274 microglia Anatomy 0.000 claims description 7
- 210000001616 monocyte Anatomy 0.000 claims description 7
- 230000003248 secreting effect Effects 0.000 claims description 7
- 238000012360 testing method Methods 0.000 claims description 7
- 208000002537 Neuronal Ceroid-Lipofuscinoses Diseases 0.000 claims description 6
- 210000001671 embryonic stem cell Anatomy 0.000 claims description 6
- 210000003958 hematopoietic stem cell Anatomy 0.000 claims description 6
- 210000004263 induced pluripotent stem cell Anatomy 0.000 claims description 6
- 230000002025 microglial effect Effects 0.000 claims description 6
- 201000008051 neuronal ceroid lipofuscinosis Diseases 0.000 claims description 6
- 238000006467 substitution reaction Methods 0.000 claims description 6
- 210000002540 macrophage Anatomy 0.000 claims description 5
- 210000003643 myeloid progenitor cell Anatomy 0.000 claims description 5
- NBSCHQHZLSJFNQ-QTVWNMPRSA-N D-Mannose-6-phosphate Chemical compound OC1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H](O)[C@@H]1O NBSCHQHZLSJFNQ-QTVWNMPRSA-N 0.000 claims description 4
- 208000033868 Lysosomal disease Diseases 0.000 claims description 4
- 208000015439 Lysosomal storage disease Diseases 0.000 claims description 4
- 150000001413 amino acids Chemical class 0.000 claims description 4
- 230000003340 mental effect Effects 0.000 claims description 4
- 239000013598 vector Substances 0.000 claims description 4
- 102000004961 Furin Human genes 0.000 claims description 3
- 101001028831 Homo sapiens Cation-independent mannose-6-phosphate receptor Proteins 0.000 claims description 3
- 210000004369 blood Anatomy 0.000 claims description 3
- 239000008280 blood Substances 0.000 claims description 3
- 230000006735 deficit Effects 0.000 claims description 3
- 230000013595 glycosylation Effects 0.000 claims description 3
- 238000006206 glycosylation reaction Methods 0.000 claims description 3
- 102000005962 receptors Human genes 0.000 claims description 3
- 108020003175 receptors Proteins 0.000 claims description 3
- 206010012289 Dementia Diseases 0.000 claims description 2
- 239000000654 additive Substances 0.000 claims description 2
- 230000032683 aging Effects 0.000 claims description 2
- 210000003995 blood forming stem cell Anatomy 0.000 claims description 2
- 210000001185 bone marrow Anatomy 0.000 claims description 2
- 238000010322 bone marrow transplantation Methods 0.000 claims description 2
- 210000003169 central nervous system Anatomy 0.000 claims description 2
- 230000019771 cognition Effects 0.000 claims description 2
- 230000006999 cognitive decline Effects 0.000 claims description 2
- 208000010877 cognitive disease Diseases 0.000 claims description 2
- 239000003085 diluting agent Substances 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 210000002304 esc Anatomy 0.000 claims description 2
- 238000007910 systemic administration Methods 0.000 claims description 2
- 238000012502 risk assessment Methods 0.000 claims 2
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 claims 1
- 229910019142 PO4 Inorganic materials 0.000 claims 1
- 150000001768 cations Chemical class 0.000 claims 1
- 210000003712 lysosome Anatomy 0.000 claims 1
- 230000001868 lysosomic effect Effects 0.000 claims 1
- 230000001537 neural effect Effects 0.000 claims 1
- 239000010452 phosphate Substances 0.000 claims 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 44
- 150000007523 nucleic acids Chemical group 0.000 description 44
- 108091033319 polynucleotide Proteins 0.000 description 18
- 102000040430 polynucleotide Human genes 0.000 description 18
- 239000002157 polynucleotide Substances 0.000 description 18
- 239000013603 viral vector Substances 0.000 description 9
- 241000712907 Retroviridae Species 0.000 description 5
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 4
- 230000008685 targeting Effects 0.000 description 4
- 108700011259 MicroRNAs Proteins 0.000 description 3
- 101710163270 Nuclease Proteins 0.000 description 3
- 239000002679 microRNA Substances 0.000 description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- 108020005345 3' Untranslated Regions Proteins 0.000 description 2
- 241000710929 Alphavirus Species 0.000 description 2
- 108091033409 CRISPR Proteins 0.000 description 2
- 108010040467 CRISPR-Associated Proteins Proteins 0.000 description 2
- 241000711573 Coronaviridae Species 0.000 description 2
- -1 GRN nucleic acids Chemical class 0.000 description 2
- 108091028066 Mir-126 Proteins 0.000 description 2
- 241000709664 Picornaviridae Species 0.000 description 2
- 241000125945 Protoparvovirus Species 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 230000002132 lysosomal effect Effects 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 210000002569 neuron Anatomy 0.000 description 2
- 239000004055 small Interfering RNA Substances 0.000 description 2
- 238000001890 transfection Methods 0.000 description 2
- 241000701161 unidentified adenovirus Species 0.000 description 2
- 241001529453 unidentified herpesvirus Species 0.000 description 2
- NODCQQSEMCESEC-UHFFFAOYSA-N 5-(1h-pyrrolo[2,3-b]pyridin-3-ylmethyl)-n-[[4-(trifluoromethyl)phenyl]methyl]pyridin-2-amine Chemical compound C1=CC(C(F)(F)F)=CC=C1CNC(N=C1)=CC=C1CC1=CNC2=NC=CC=C12 NODCQQSEMCESEC-UHFFFAOYSA-N 0.000 description 1
- NSMOZFXKTHCPTQ-UHFFFAOYSA-N 6-fluoro-n-[(5-fluoro-2-methoxypyridin-3-yl)methyl]-5-[(5-methyl-1h-pyrrolo[2,3-b]pyridin-3-yl)methyl]pyridin-2-amine Chemical compound COC1=NC=C(F)C=C1CNC(N=C1F)=CC=C1CC1=CNC2=NC=C(C)C=C12 NSMOZFXKTHCPTQ-UHFFFAOYSA-N 0.000 description 1
- 241001655883 Adeno-associated virus - 1 Species 0.000 description 1
- 241000702423 Adeno-associated virus - 2 Species 0.000 description 1
- 241000202702 Adeno-associated virus - 3 Species 0.000 description 1
- 241000580270 Adeno-associated virus - 4 Species 0.000 description 1
- 241001634120 Adeno-associated virus - 5 Species 0.000 description 1
- 241000972680 Adeno-associated virus - 6 Species 0.000 description 1
- 241001164823 Adeno-associated virus - 7 Species 0.000 description 1
- 241001164825 Adeno-associated virus - 8 Species 0.000 description 1
- 241000649045 Adeno-associated virus 10 Species 0.000 description 1
- 102000035485 Allograft inflammatory factor 1 Human genes 0.000 description 1
- 108091010877 Allograft inflammatory factor 1 Proteins 0.000 description 1
- 208000031277 Amaurotic familial idiocy Diseases 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- 208000011597 CGF1 Diseases 0.000 description 1
- 238000010354 CRISPR gene editing Methods 0.000 description 1
- 102100039196 CX3C chemokine receptor 1 Human genes 0.000 description 1
- 206010012218 Delirium Diseases 0.000 description 1
- 241000702421 Dependoparvovirus Species 0.000 description 1
- 229920002491 Diethylaminoethyl-dextran Polymers 0.000 description 1
- 101000746022 Homo sapiens CX3C chemokine receptor 1 Proteins 0.000 description 1
- 101001046686 Homo sapiens Integrin alpha-M Proteins 0.000 description 1
- 101000916644 Homo sapiens Macrophage colony-stimulating factor 1 receptor Proteins 0.000 description 1
- 101000934372 Homo sapiens Macrosialin Proteins 0.000 description 1
- 102100022338 Integrin alpha-M Human genes 0.000 description 1
- 102100028198 Macrophage colony-stimulating factor 1 receptor Human genes 0.000 description 1
- 102100025136 Macrosialin Human genes 0.000 description 1
- 102100026171 P2Y purinoceptor 12 Human genes 0.000 description 1
- 102000010292 Peptide Elongation Factor 1 Human genes 0.000 description 1
- 108010077524 Peptide Elongation Factor 1 Proteins 0.000 description 1
- 102100028251 Phosphoglycerate kinase 1 Human genes 0.000 description 1
- 101710139464 Phosphoglycerate kinase 1 Proteins 0.000 description 1
- 229920002873 Polyethylenimine Polymers 0.000 description 1
- 108010014270 Purinergic P2Y12 Receptors Proteins 0.000 description 1
- 108020005067 RNA Splice Sites Proteins 0.000 description 1
- 208000018642 Semantic dementia Diseases 0.000 description 1
- 108091027967 Small hairpin RNA Proteins 0.000 description 1
- 108020004459 Small interfering RNA Proteins 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 102100037029 Transmembrane protein 119 Human genes 0.000 description 1
- 101710170979 Transmembrane protein 119 Proteins 0.000 description 1
- YCPOZVAOBBQLRI-WDSKDSINSA-N Treosulfan Chemical compound CS(=O)(=O)OC[C@H](O)[C@@H](O)COS(C)(=O)=O YCPOZVAOBBQLRI-WDSKDSINSA-N 0.000 description 1
- 241001492404 Woodchuck hepatitis virus Species 0.000 description 1
- 108010017070 Zinc Finger Nucleases Proteins 0.000 description 1
- 230000000735 allogeneic effect Effects 0.000 description 1
- 201000007201 aphasia Diseases 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 230000008499 blood brain barrier function Effects 0.000 description 1
- 210000001218 blood-brain barrier Anatomy 0.000 description 1
- 229960002092 busulfan Drugs 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 229920006317 cationic polymer Polymers 0.000 description 1
- ACSIXWWBWUQEHA-UHFFFAOYSA-N clodronic acid Chemical compound OP(O)(=O)C(Cl)(Cl)P(O)(O)=O ACSIXWWBWUQEHA-UHFFFAOYSA-N 0.000 description 1
- 229960002286 clodronic acid Drugs 0.000 description 1
- 239000000412 dendrimer Substances 0.000 description 1
- 229920000736 dendritic polymer Polymers 0.000 description 1
- 230000000779 depleting effect Effects 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 238000000530 impalefection Methods 0.000 description 1
- 230000008449 language Effects 0.000 description 1
- 230000013016 learning Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000015654 memory Effects 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000012466 permeate Substances 0.000 description 1
- JGWRKYUXBBNENE-UHFFFAOYSA-N pexidartinib Chemical compound C1=NC(C(F)(F)F)=CC=C1CNC(N=C1)=CC=C1CC1=CNC2=NC=C(Cl)C=C12 JGWRKYUXBBNENE-UHFFFAOYSA-N 0.000 description 1
- 230000001124 posttranscriptional effect Effects 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000036362 sensorimotor function Effects 0.000 description 1
- 230000004039 social cognition Effects 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 230000002463 transducing effect Effects 0.000 description 1
- 229960003181 treosulfan Drugs 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024231791A JP2025060943A (ja) | 2019-02-01 | 2024-12-27 | 神経認知障害を処置するための組成物及び方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962800096P | 2019-02-01 | 2019-02-01 | |
| US62/800,096 | 2019-02-01 | ||
| PCT/US2020/016192 WO2020160458A1 (en) | 2019-02-01 | 2020-01-31 | Compositions and methods for treating neurocognitive disorders |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024231791A Division JP2025060943A (ja) | 2019-02-01 | 2024-12-27 | 神経認知障害を処置するための組成物及び方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022523913A JP2022523913A (ja) | 2022-04-27 |
| JPWO2020160458A5 true JPWO2020160458A5 (enrdf_load_stackoverflow) | 2023-04-25 |
Family
ID=71841663
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021544547A Pending JP2022523913A (ja) | 2019-02-01 | 2020-01-31 | 神経認知障害を処置するための組成物及び方法 |
| JP2024231791A Pending JP2025060943A (ja) | 2019-02-01 | 2024-12-27 | 神経認知障害を処置するための組成物及び方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024231791A Pending JP2025060943A (ja) | 2019-02-01 | 2024-12-27 | 神経認知障害を処置するための組成物及び方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20220111005A1 (enrdf_load_stackoverflow) |
| EP (1) | EP3917539A4 (enrdf_load_stackoverflow) |
| JP (2) | JP2022523913A (enrdf_load_stackoverflow) |
| CA (1) | CA3128003A1 (enrdf_load_stackoverflow) |
| IL (1) | IL285269A (enrdf_load_stackoverflow) |
| MA (1) | MA54874A (enrdf_load_stackoverflow) |
| WO (1) | WO2020160458A1 (enrdf_load_stackoverflow) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2022553307A (ja) * | 2019-10-22 | 2022-12-22 | アプライド ジェネティック テクノロジーズ コーポレイション | プログラニュリン関連神経変性疾患または障害の治療のためのアデノ随伴ウイルス（ａａｖ）システム |
| US20230193212A1 (en) * | 2020-05-06 | 2023-06-22 | Orchard Therapeutics (Europe) Limited | Treatment for neurodegenerative diseases |
| BR112022016715A2 (pt) * | 2020-05-27 | 2022-11-16 | Univ Zuerich | Vetores virais que expressam proteínas terapêuticos especificamente em células mieloides e microglia |
| JP2021079225A (ja) * | 2021-03-01 | 2021-05-27 | 株式会社三洋物産 | 遊技機 |
| JP2021087836A (ja) * | 2021-03-01 | 2021-06-10 | 株式会社三洋物産 | 遊技機 |
| US20240342207A1 (en) * | 2021-08-02 | 2024-10-17 | Board Of Regents, The University Of Texas System | Modified nucleic acid compositions and associated methods for treatment of phenylketonuria |
| CN119233981A (zh) * | 2022-04-08 | 2024-12-31 | 塑造治疗公司 | 用于组织特异性表达的启动子开关 |
| JP7556434B2 (ja) * | 2022-08-22 | 2024-09-26 | 株式会社三洋物産 | 遊技機 |
| JP7556432B2 (ja) * | 2022-08-22 | 2024-09-26 | 株式会社三洋物産 | 遊技機 |
| JP7556433B2 (ja) * | 2022-08-22 | 2024-09-26 | 株式会社三洋物産 | 遊技機 |
| WO2024189094A1 (en) * | 2023-03-14 | 2024-09-19 | UCB Biopharma SRL | Gene therapy |
| WO2024205404A1 (en) * | 2023-03-27 | 2024-10-03 | Sanquin IP B.V. | Novel capsid engineered aav vectors for liver-directed gene therapy |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69029737T2 (de) * | 1989-10-16 | 1997-06-19 | Hem Pharma Corp | Diagnose und behandlung von neuro-cognitiven störungen assoziiert mit systemisch-immunologischer fehlfunktion |
| ES2152483T3 (es) | 1992-11-13 | 2001-02-01 | Idec Pharma Corp | Aplicacion terapeutica en anticuerpos quimericos y radiomarcados contra el antigeno de diferenciacion restringida de los linfocitos b humanos para el tratamiento del linfoma de celulas b. |
| US20050163760A1 (en) * | 2001-12-06 | 2005-07-28 | Nathalie Cartier-Lacave | Use of cd34+ hematopoietic progenitor cells for the treatment of cns disorders |
| US8486635B2 (en) * | 2006-05-30 | 2013-07-16 | Mayo Foundation For Medical Education And Research | Detecting and treating dementia |
| MX2008015530A (es) * | 2006-06-07 | 2009-02-06 | Genzyme Corp | Terapia genica para esclerosis lateral amiotrofica y otros trastornos de la medula espinal. |
| CN102006882B (zh) * | 2008-01-16 | 2017-06-06 | 神经动力公司 | 利用颗粒体蛋白前体(pgrn)治疗神经变性疾病 |
| WO2010022175A1 (en) * | 2008-08-19 | 2010-02-25 | Yale University | Identification of sortilin as a neuronal receptor for the frontotemporal dementia protein, progranulin |
| FI4342992T3 (fi) * | 2009-05-02 | 2025-08-12 | Genzyme Corp | Geenihoito neurodegeneratiivisiin sairauksiin |
| US20110203007A1 (en) * | 2010-02-16 | 2011-08-18 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Assays of neurodegenerative disorders, including frontotemporal dementia and amyotrophic lateral sclerosis |
| US20150352185A1 (en) * | 2010-11-16 | 2015-12-10 | Denis G. Kay | Method for increasing neprilysin expression and activity |
| WO2017151884A1 (en) | 2016-03-02 | 2017-09-08 | The Children's Hospital Of Philadelphia | Therapy for frontotemporal dementia |
| US20210284701A1 (en) * | 2016-07-14 | 2021-09-16 | Emory University | Granulin Compositions and Uses Related Thereto |
| US11806367B2 (en) * | 2017-03-15 | 2023-11-07 | The Regents Of The University Of California | Methods of treating lysosomal disorders |
| SG11202108504YA (en) * | 2019-02-22 | 2021-09-29 | Univ Pennsylvania | Recombinant adeno-associated virus for treatment of grn-associated adult-onset neurodegeneration |
-
2020
- 2020-01-31 EP EP20748326.4A patent/EP3917539A4/en active Pending
- 2020-01-31 US US17/427,298 patent/US20220111005A1/en active Pending
- 2020-01-31 JP JP2021544547A patent/JP2022523913A/ja active Pending
- 2020-01-31 WO PCT/US2020/016192 patent/WO2020160458A1/en unknown
- 2020-01-31 CA CA3128003A patent/CA3128003A1/en active Pending
- 2020-01-31 MA MA054874A patent/MA54874A/fr unknown
-
2021
- 2021-08-01 IL IL285269A patent/IL285269A/en unknown
-
2024
- 2024-12-27 JP JP2024231791A patent/JP2025060943A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2015364636B9 (en) | Gene therapy for Juvenile Batten Disease | |
| JP6683691B2 (ja) | 高効率ゲノム編集のためのアデノ随伴ウイルスベクターバリアント及びその方法 | |
| JP2025015673A (ja) | 脊髄軟膜下遺伝子送達システム | |
| ES2615180T3 (es) | Métodos y composiciones para el tratamiento de enfermedades cerebrales | |
| JP2022508182A (ja) | 組換えウイルスベクター及びそれの産生のための核酸 | |
| EP3546584B1 (en) | Compositions for treating lysosmal storage disease (lsd) | |
| EP2500434A1 (en) | Capsid-free AAV vectors, compositions, and methods for vector production and gene delivery | |
| US20100111911A1 (en) | Mitochondrial nucleic acid delivery systems | |
| JPWO2020160458A5 (enrdf_load_stackoverflow) | ||
| CN114072514A (zh) | 用于治疗atp酶介导的疾病的组合物和方法 | |
| CN114127296B (zh) | Ube3a基因和表达盒及其应用 | |
| Chatterjee et al. | Adeno-associated virus and hematopoietic stem cells: the potential of adeno-associated virus hematopoietic stem cells in genetic medicines | |
| JPWO2020160468A5 (enrdf_load_stackoverflow) | ||
| Von Jonquieres et al. | Emerging concepts in vector development for glial gene therapy: implications for leukodystrophies | |
| US20230190893A1 (en) | Compositions and methods for treating an inherited retinal disease | |
| Koppanati et al. | Improvement of the mdx mouse dystrophic phenotype by systemic in utero AAV8 delivery of a minidystrophin gene | |
| JPWO2019173756A5 (enrdf_load_stackoverflow) | ||
| JPWO2020160441A5 (enrdf_load_stackoverflow) | ||
| US20240067942A1 (en) | Lysosomal acid lipase variants and uses thereof | |
| Silver et al. | Towards a rAAV-based gene therapy for ADA-SCID: from ADA deficiency to current and future treatment strategies | |
| US20240156873A1 (en) | Methods to genetically engineer hematopoietic stem and progenitor cells for red cell specific expression of therapeutic proteins | |
| Segurado | Introduction to AAV‐based in vivo Gene Therapy | |
| JP2024542015A (ja) | 脳内でのｔｃｆ７ｌ２媒介性髄鞘再生 | |
| WO2025094056A1 (en) | Gene therapy constructs and methods of use therefor | |
| WO2025188625A1 (en) | Recombinant adeno-associated virus for treatment of neurodegenerative disorders |